Healthcare Value Capital’s Viking Therapeutics VKTX Stock Holding History

Healthcare Value Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-250,000	Closed	-$1.54M	–	27
2019 Q4	$2M	Hold	250,000	–	–	5.9%	6
2019 Q3	$1.72M	Hold	250,000	–	–	3.11%	10
2019 Q2	$2.08M	Hold	250,000	–	–	3.89%	12
2019 Q1	$2.48M	Buy	250,000 +150,000	+150%	+$1.26M	9.57%	6
2018 Q4	$765K	Sell	100,000 -50,000	-33%	-$598K	2.97%	8
2018 Q3	$2.61M	Hold	150,000	–	–	6.32%	8
2018 Q2	$1.42M	Buy	+150,000	New	+$998K	4.04%	9

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Healthcare Value Capital's VKTX Position: Q1 2020 in Review

Healthcare Value Capital sold out of Viking Therapeutics (VKTX) in Q1 2020, closing a stake of 250,000 shares — an estimated $1.54M sold.

Healthcare Value Capital first reported a position in VKTX in Q2 2018 and held it in 7 quarters. The position peaked at $2.61M in Q3 2018. 137 funds tracked by Wall St. Rank hold VKTX as of Q1 2020.

Healthcare Value Capital reported no remaining Viking Therapeutics position as of Q1 2020 after selling out during the quarter.
Healthcare Value Capital sold 250,000 Viking Therapeutics shares in Q1 2020, an estimated $1.54M.
Healthcare Value Capital first reported a position in Viking Therapeutics in Q2 2018 and held it in 7 quarters.
Healthcare Value Capital's Viking Therapeutics position peaked at $2.61M in Q3 2018.
137 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2020.

Based on Healthcare Value Capital's 13F filing for Q1 2020, filed 15 May 2020.